• Vaccine Name: rHA with IL-1β adjuvant
• Target Pathogen: Influenza virus
• Target Disease: Influenza (flu)
• Vaccine Ontology ID: VO_0004235
• Type: Subunit vaccine
• Status: Research
• Antigen: Baculovirus-expressed recombinant influenza virus hemagglutinin (rHA) derived from influenza virus A/New Caledonia/20/1999 (Kayamuro et al., 2010).
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0001297
• Immunization Route: intranasal immunization

Mouse Response

• Vaccination Protocol: Mice were immunized intranasally with rHA alone (1 µg/mouse), rHA (1 µg/mouse) plus CT (1 µg/mouse), or rHA (1 µg/mouse) plus one of the IL cytokines (0.1 µg, 0.3 µg, or 1.0 µg/mouse) on days 0 and 28 (Kayamuro et al., 2010).
• Immune Response: Immunization with rHA plus IL-1{alpha}, IL-1β, IL-18, or IL-33, referred to as IL-1 family cytokines, resulted in the highest rHA-specific IgG responses among the IL cytokines. IL-1β elicited both Th1- and Th2-type cytokine responses (Kayamuro et al., 2010).
• Challenge Protocol: Fourteen days after the final immunization, mice were fully anesthetized by intraperitoneal injection of pentobarbital, and each was infected by intranasal application of 25 µl PBS containing 256 hemagglutinating units (HAU) of influenza virus A/PR/8/34 (H1N1) (Kayamuro et al., 2010).
• Efficacy: Mice immunized with PR8 HA plus IL-1β or IL-18 had 100% survival 14 days after challenge, though with a slight loss of body weight (Kayamuro et al., 2010).